NCT02096952View on ClinicalTrials.gov

Methylphenidate ER Liquid Formulation in Adults With ASD and ADHD

PHASE4CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

May 31, 2014

Primary Completion Date

January 31, 2018

Study Completion Date

January 31, 2018

Conditions
Attention-deficit/Hyperactivity DisorderAutism Spectrum Disorder
Interventions
DRUG

Methylphenidate extended-release liquid formulation

Trial Locations (1)

02144

Massachusetts General Hospital, Boston

All Listed Sponsors
lead

Massachusetts General Hospital

OTHER

NCT02096952 - Methylphenidate ER Liquid Formulation in Adults With ASD and ADHD | Biotech Hunter | Biotech Hunter